English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Open

Objective  To investigate the efficacy and safety of ixekizumab in patients with active radiographic axial spondyloarthritis (SpA) and prior inadequate response to or intolerance of 1 or 2 tumor necrosis factor inhibitors ( TNF i).    Methods  In this phase  III  randomized, double‐blind, placebo‐controlled trial, adult patients with an inadequate response to or intolerance of 1 or 2  TNF i and an established diagnosis of axial SpA (according to the Assessment of SpondyloArthritis international Society [ ASAS ] criteria for radiographic axial SpA, with radiographic sacroiliitis defined according to the modified New York criteria and ≥1 feature of SpA) were recruited and randomized 1:1:1 to receive placebo or 80‐mg subcutaneous ixekizumab every 2 weeks ( IXE Q2W) or 4 weeks ( IXEQ4W ), with an 80‐mg or 160‐mg starting dose. The primary end point was 40% improvement in disease activity according to the  ASAS  criteria ( ASAS 40) at week 16. Secondary outcomes and safety were also assessed.    Results  A total of 316 patients were randomized to receive placebo (n = 104),  IXEQ2W  (n = 98), or  IXEQ4W  (n = 114). At week 16, significantly higher proportions of  IXEQ2W  patients (n = 30 [30.6%];  P  = 0.003) or  IXEQ4W  patients (n = 29 [25.4%];  P  = 0.017) had achieved an  ASAS 40 response versus the placebo group (n = 13 [12.5%]), with statistically significant differences reported as early as week 1 with ixekizumab treatment. Statistically significant improvements in disease activity, function, quality of life, and spinal magnetic resonance imaging–evident inflammation were observed after 16 weeks of ixekizumab treatment versus placebo. Treatment‐emergent adverse events ( AE s) with ixekizumab treatment were more frequent than with placebo. Serious  AE s were similar across treatment arms. One death was reported ( IXEQ2W  group).    Conclusion  Ixekizumab treatment for 16 weeks in patients with active radiographic axial SpA and previous inadequate response to or intolerance of 1 or 2  TNF i yields rapid and significant improvements in the signs and symptoms of radiographic axial SpA versus placebo.

arthritis and rheumatology

Efficacy and Safety of Ixekizumab in the Treatment of Radiographic Axial Spondyloarthritis: Sixteen‐Week Results From a Phase  III  Randomized, Double‐Blind, Placebo‐Controlled Trial in Patients With Prior Inadequate Response to or Intolerance of Tumor Necrosis Factor Inhibitors